Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun;466(6):1151-62.
doi: 10.1007/s00424-014-1462-x. Epub 2014 Feb 8.

Heart failure-specific changes in protein kinase signalling

Affiliations
Review

Heart failure-specific changes in protein kinase signalling

Kristina Lorenz et al. Pflugers Arch. 2014 Jun.

Abstract

Among the myriad of molecular alterations occurring in heart failure development, aggravation of the disease is often attributed to global or local changes in protein kinase activity, thus making protein kinases attractive targets for therapeutic intervention. Since protein kinases do not only have maladaptive roles, but also contribute to the physiological integrity of cells, it is a challenging task to circumvent undesired inhibition of protein kinase activity. Identification of posttranslational modifications and/or protein-protein interactions that are exclusively apparent under pathophysiological conditions provides exciting information for alternative non-kinase inhibitory treatment strategies that eliminate maladaptive functions of a protein kinase, but preserve the beneficial ones. Here, we focus on the disease-specific regulation of a number of protein kinases, namely, Ca(2+)/calmodulin-dependent protein kinase II isoform δ (CaMKIIδ), G protein-coupled receptor kinase 2 (GRK2), extracellular signal-regulated kinase 1 and 2 (ERK1/2), protein kinase D (PKD) and protein kinase C isoform β2 (PKCβ2), which are embedded in complex signal transduction pathways implicated in heart failure development, and discuss potential avenues for novel treatment strategies to combat heart disease.

PubMed Disclaimer

References

    1. J Mol Biol. 2006 Dec 15;364(5):955-63 - PubMed
    1. ACS Chem Biol. 2012 Nov 16;7(11):1830-9 - PubMed
    1. N Engl J Med. 1982 Jul 22;307(4):205-11 - PubMed
    1. Mol Pharmacol. 2011 Oct;80(4):551-7 - PubMed
    1. Science. 2002 Oct 25;298(5594):834-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources